What are the challenges in targeting G6PD for cancer treatment?
While targeting G6PD presents a promising approach, several challenges need to be addressed. Firstly, the development of selective inhibitors that do not affect normal cells is crucial, as G6PD is also important for the function of non-cancerous tissues. Additionally, cancer cells are known to exhibit metabolic flexibility, potentially compensating for the loss of G6PD activity through alternative pathways. Understanding the metabolic adaptations that cancer cells may employ is necessary to design effective combination therapies. Finally, inter-individual variability in G6PD activity, such as genetic polymorphisms leading to G6PD deficiency, must be considered to avoid adverse effects in patients.
